This Pharmaceutical Company Just Got a Major Boost
The chances are good that you've heard the name Pfizer (NYSE: PFE) more in the past 18 months than in all of your years combined before the COVID-19 pandemic hit. Once vaccines started rolling out, Pfizer news became commonplace. Now, it's that branded name recognition that could help bolster sales of a therapeutic treatment in Canada for another pharmaceutical company.
HLS Therapeutics (TSX: HLS) announced on Aug. 16 that it has reached an agreement with Pfizer to co-market Vascepa in Canada. Vascepa, an innovative therapeutic prescription medicine for treating cardiovascular disease, is used in conjunction with medicines called statins, such as Pfizer's Lipitor, which help fight high cholesterol and reduce heart attack and stroke.
The drug has been FDA-approved and marketed in the U.S. by Amarin since 2019. Can Pfizer's name recognition and resources help boost sales for HLS in Canada?
Source Fool.com
